prasterone + acolbifene

A combination therapy of **prasterone** (dehydroepiandrosterone; DHEA), a synthetic androgen, estrogen, and neurosteroid, and **acolbifene**, a selective estrogen receptor modulator (SERM)[1][3]. Developed for the treatment of **vasomotor symptoms (hot flashes)** in postmenopausal women[1][3]. Prasterone acts primarily as a precursor hormone that can be converted into active an­drogens and estrogens, while acolbifene modulates estrogen receptor activity, inhibiting both agonist and antagonist actions on the receptor[3]. Oral administration is the intended route[1][3]. The product is under development by Endoceutics and has reached **Phase III clinical trials** for vasomotor symptoms; its investigation in other indications (osteoporosis, breast cancer, decreased libido, hypogonadism) was discontinued or not further developed[3].

Brand names

Femivia

Other names

Prasterone/acolbifeneDehydroepiandrosterone/acolbifeneDHEA/acolbifeneacolbifene/prasterone